Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells.
Zhang W, Bao L, Yang S, Qian Z, Dong M, Yin L, Zhao Q, Ge K, Deng Z, Zhang J, Qi F, An Z, Yu Y, Wang Q, Wu R, Fan F, Zhang L, Chen X, Na Y, Feng L, Liu L, Zhu Y, Qin T, Zhang S, Zhang Y, Zhang X, Wang J, Yi X, Zou L, Xin HW, Ditzel HJ, Gao H, Zhang K, Liu B, Cheng S.
Zhang W, et al. Among authors: wang j, wang q.
Oncotarget. 2016 Jun 28;7(26):39768-39783. doi: 10.18632/oncotarget.9465.
Oncotarget. 2016.
PMID: 27206795
Free PMC article.